Related Experiment Video
Updated: May 26, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Pulmonary aspergillosis: recent advances
George R Thompson1, Thomas F Patterson
1Department of Medical Microbiology and Immunology, University of California-Davis, Davis, California, USA. grthompson@ucdavis.edu
Abstract:
Aspergillosis remains a significant cause of morbidity and mortality. The spectrum of disease is diverse and ranges from noninvasive disease with an excessive immune response, such as in allergic bronchopulmonary aspergillosis (ABPA), to a lack of an immune response as seen in patients with quantitative or qualitative granulocyte deficits and subsequent invasive pulmonary aspergillosis. Noninvasive diagnostic testing has improved the time to initiation of effective antifungal therapy, and numerous agents in different therapeutic classes are now available as treatment options. Voriconazole remains the preferred agent in the treatment of invasive pulmonary aspergillosis, and recent data have increased interest in the potential of combination therapy against this often lethal infection. The role of host genetics in selecting patients that may benefit from more aggressive antifungal prophylaxis or treatment practices remains unclear but is likely to guide therapeutic choices as newer data become available.
Insights
Aspergillosis, a serious fungal infection, presents diverse disease forms. Early diagnosis and antifungal treatments like voriconazole are crucial, with combination therapy showing promise for invasive cases.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pulmonology
Background:
- Aspergillosis significantly contributes to patient morbidity and mortality.
- Disease presentation varies from noninvasive allergic bronchopulmonary aspergillosis (ABPA) to invasive pulmonary aspergillosis in immunocompromised individuals.
- Advances in diagnostics and antifungal agents have improved treatment outcomes.
Purpose of the Study:
- To review the current landscape of aspergillosis diagnosis and treatment.
- To highlight the role of voriconazole and emerging combination therapies.
- To discuss the potential impact of host genetics on therapeutic strategies.
Main Methods:
- Literature review of diagnostic advancements.
- Analysis of current antifungal treatment options, including voriconazole.
- Discussion of emerging therapeutic strategies and host genetic factors.
Main Results:
- Noninvasive diagnostics expedite antifungal therapy initiation.
- Voriconazole is the preferred treatment for invasive pulmonary aspergillosis.
- Combination therapy is gaining interest for severe infections.
Conclusions:
- Effective management of aspergillosis relies on timely diagnosis and appropriate antifungal selection.
- Future treatment strategies may incorporate host genetic information for personalized prophylaxis and therapy.
Related Concept Videos
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Pneumonia II: Pathophysiology
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pneumonia I: Introduction
